Steven L. Krill is CSO & VP at EAGLE PHARMACEUTICALS, INC. (EGRX). They have made 13 open-market trades across 1 company since 2015, most recently 2018-01-07.
CIK 0000827871
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 13 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| EGRX | 3,000 | $6K |
Shares reported on the most recent Form 4, priced at the 2018-01-09 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| EGRX | SELL | 2017-03-23 | 2017-03-24 | $82.06 | $576K | +3.1% | +10.4% | +0.8% |
| EGRX | SELL | 2017-03-22 | 2017-03-24 | $81.40 | $1.7M | +3.1% | +10.4% | +0.8% |
| EGRX | SELL | 2017-03-22 | 2017-03-24 | $80.09 | $569K | +3.1% | +10.4% | +0.8% |
| EGRX | SELL | 2016-12-23 | 2017-01-04 | $78.61 | $403K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-22 | 2017-01-04 | $76.78 | $394K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-21 | 2017-01-04 | $77.17 | $791K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-20 | 2017-01-04 | $76.69 | $767K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-19 | 2017-01-04 | $75.61 | $756K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-15 | 2017-01-04 | $74.79 | $748K | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-15 | 2017-01-04 | $76.37 | $7.0M | -18.0% | -16.5% | -0.3% |
| EGRX | SELL | 2016-12-13 | 2016-12-15 | $73.62 | $736K | +5.8% | -5.7% | +10.9% |
| EGRX | SELL | 2016-11-23 | 2016-12-02 | $80.00 | $479K | -1.2% | +5.8% | -0.8% |
| EGRX | SELL | 2015-06-16 | 2015-06-18 | $81.60 | $814K | -8.4% | -0.4% | -0.4% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.